Pharsight

Seasonique is owned by Teva Branded Pharm.

Seasonique contains Ethinyl Estradiol; Levonorgestrel.

Seasonique has a total of 4 drug patents out of which 0 drug patents have expired.

Seasonique was authorised for market use on 25 May, 2006.

Seasonique is available in tablet;oral dosage forms.

Seasonique can be used as prevention of pregnancy, prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

The generics of Seasonique are possible to be released after 05 December, 2028.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545	TEVA BRANDED PHARM	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology	Jun, 2023 (4 months from now)
US7858605	TEVA BRANDED PHARM	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology	Jun, 2023 (4 months from now)
US7320969	TEVA BRANDED PHARM	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology	Jan, 2024 (11 months from now)
US7855190	TEVA BRANDED PHARM	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration	Dec, 2028 (5 years from now)